Asked by: Jonathan Ashworth (Labour (Co-op) - Leicester South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, pursuant to the Answer of 13 November 2017 to Question 111309, on Genito-urinary Medicine: Greater London, if he will place in the Library the specialist advice given to the London Sexual Health Transformation Programme by Public Health England on (a) best practice, (b) behavioural change approaches and (c) the evaluation and development of service standards.
Answered by Steve Brine
Co-commissioning and collaboration by commissioners offers an efficient way for delivery of sexual health services. To support commissioning bodies to ensure the delivery of high quality sexual health, reproductive health and HIV services, in line with their responsibilities set out in the Health and Social Care Act 2012, Public Health England (PHE) produced the Making It Work guidance in 2015. It is available at the following link:
Specialist advice to the London Sexual Health Transformation Programme has been provided by PHE as part of the collaborative, multidisciplinary approach to the programme on an ongoing basis. This included advice on the clinical specification as part of the
multidisciplinary clinical advisory group which produced a template specification for physical clinical services. Unwritten advice has been given on the evaluation which we would expect to produce written products in due course.
PHE has not allocated funding to support the London Sexual Health Transformation Programme.
Responsibility for commissioning open access sexual health services is devolved to local authorities through the Health and Social Care Act 2012. PHE does not engage in the detailed procurement process of individual services but we understand arrangements for physical or online service delivery are being put in place locally.
Asked by: Afzal Khan (Labour - Manchester, Gorton)
Question to the Cabinet Office:
To ask the Minister for the Cabinet Office, which (a) groups and (b) organisations were involved in stakeholder consultation exercises as part of the Race Disparity Audit, broken down by (i) sector, (ii) race and (iii) ethnicity.
Answered by Damian Green
All UK Government Departments, the Office for National Statistics, the UK Statistics Authority and all three Devolved Administrations have been consulted about the development of the Audit. Outside organisations consulted about the Race Disparity Audit are listed below. Data is not held on the race or ethnicity of individuals who were consulted.
Academic sector
Academy Of Medical Sciences
Birkbeck College, University of London
Bristol University
British Academy
Huddersfield University
London School of Economics
NatCen Social Research
Royal Society
Sheffield University
Universities UK
University of Edinburgh
University of Essex
University of London
University of Manchester
University of Oxford
University of Sheffield
Non-Government Organisations
Belong
BEMIS Scotland
Big Lottery Fund
Bite the Ballot
Black Thrive
Black Training and Enterprise Group
BME Health Forum
BRAP
British Heart Foundation
Business in the Community
Cancer Research UK
CEMVO Scotland
Changing the Chemistry (CtC)
Chinese Health Living Centre
Citizens Advice
Data Orchard
Education and Employers Taskforce
Employers Network for Equality and Inclusion
Equality and Diversity Forum
Equality and Human Rights Commission
Friends, Families and Travellers
FullFact
Gypsy Traveller Empowerment
Inclusion Cornwall
Institute for Public Policy Research
Joseph Rowntree Foundation
Kings Fund
National Black Women’s Network
Northern Ireland Council for Racial Equality
Office for Fair Access
Olmec
One Voice For Travellers
Open Data Institute
Operation Black Vote
QED UK
Race Equality Foundation
Race on the Agenda
RJ Working
Roma Support Group
Royal Academy of Engineering
Royal College of Psychiatrists
Runnymede Trust
St Giles Trust
The Leeds GATE
Voice 4 Change
Work Foundation
Young Foundation
Private sector
Green Park Ltd
Public sector
Bradford City Council
Bradford College
Bradford Health and Well Being Board
Camden Council
City of London Academies Trust
Cornwall Council
Greater London Authority
Hackney Council
Haringey Council
Harris Federation
Higher Education Funding Council for England
Lambeth Council
Office for Students
NHS BME Network
NHS Kernow Clinical Commissioning Group
NHS Yorkshire and Humber Commissioning Support
Royal Cornwall Hospital Trust
Sheffield Council
South London and Maudsley NHS Trust
Asked by: Jonathan Ashworth (Labour (Co-op) - Leicester South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, how much public funding pharmacies have received for providing (a) essential and (b) advanced services in each year since 2007-08 in (i) England and (ii) each local authority area.
Answered by Steve Brine
The fees and allowances paid under the community pharmacy contractual framework for essential and advanced services provided by community pharmacies each year from April 2011 to May 2017 are detailed in the table below. This is based on NHS Business Services Authority data, which in line with their records management policy is only available for six financial years plus the current year. These payments do not include the medicine margin community pharmacies are allowed to earn as part of the payment for essential services, which is paid through reimbursement within the drugs’ bill.
Time Period | Essential Services Fees and Allowances1 (£) | Advanced Services Fees2 (£) |
2011/12 | 1,864,457,518.09 | 78,082,359.62 |
2012/13 | 1,847,685,380.92 | 96,603,659.09 |
2013/14 | 1,908,705,835.81 | 105,000,556.12 |
2014/15 | 1,895,070,668.01 | 108,034,310.82 |
2015/16 | 1,881,141,079.50 | 112,536,351.89 |
2016/17 | 1,752,244,281.27 | 115,311,548.44 |
April – May 2017 | 254,235,060.58 | 19,263,189.52 |
Total | 11,403,539,824.18 | 634,831,975.50 |
Notes:
1This comprises the fees and allowances paid under Part IIIA: Professional Fees (Pharmacy Contractors) and Part VIA: Payment for Essential Services (Pharmacy Contractors) of the Drug Tariff.
2 This comprises the fees paid to pharmacy contractors under Part VIC: Advanced Services (Pharmacy and Appliance Contractors)(England) of the Drug Tariff with the exception of the Community Pharmacy Seasonal Flu Vaccination Advanced Service and the NHS Urgent Medicine Supply Advanced Service pilot scheme, which are separately funded by NHS England.
Essential and advanced services under the community pharmacy contractual framework are commissioned and funded by the National Health Service, rather than local authorities. A breakdown of fees and allowances paid for essential and advanced services provided by community pharmacies by NHS England Area from April 2013 (when NHS England was established) to May 2017 is detailed in the table below:
| April 2013 – May 2017 | |
NHS England Area | Essential Services Fees and Allowances1 (£) | Advanced Services Fees2 (£) |
Arden, Hereford and Worcester | 227,173,105.87 | 12,471,806.00 |
Bath, Gloucester, Swindon and Wiltshire | 194,264,861.16 | 10,698,397.64 |
Birmingham and the Black Country | 382,048,149.30 | 24,479,481.00 |
Bristol, North Somerset, Somerset and South Gloucester | 203,844,336.59 | 12,535,700.84 |
Cheshire, Warrington and Wirral | 196,741,140.51 | 11,818,010.92 |
Cumbria, Northumbria, Tyne and Wear | 346,096,424.54 | 16,101,508.76 |
Derbyshire and Nottinghamshire | 280,954,214.40 | 17,394,417.84 |
Devon, Cornwall and Isles of Scilly | 243,978,967.48 | 14,688,545.28 |
Durham, Darlington and Tees | 228,795,999.17 | 9,639,507.48 |
East Anglia | 310,112,463.57 | 18,804,613.20 |
Essex | 237,137,272.03 | 14,470,338.40 |
Greater Manchester | 468,751,127.40 | 27,327,097.22 |
Hertfordshire and South Midlands | 359,111,434.98 | 22,494,201.30 |
Kent and Medway | 237,213,904.62 | 14,107,079.36 |
Lancashire | 263,368,765.04 | 15,234,732.32 |
Leicestershire and Lincolnshire | 249,852,782.65 | 14,583,791.92 |
Merseyside | 227,811,833.19 | 12,899,454.56 |
North East London | 384,832,821.86 | 26,726,691.28 |
North West London | 248,519,307.32 | 17,040,248.44 |
North Yorkshire and Humber | 245,869,738.16 | 13,235,273.20 |
Shropshire and Staffordshire | 235,256,866.36 | 13,260,886.28 |
South London | 358,363,508.73 | 25,058,335.56 |
South Yorkshire and Bassetlaw | 266,634,566.98 | 15,480,457.12 |
Surrey and Sussex | 341,873,405.61 | 23,686,281.31 |
Thames Valley | 222,827,674.68 | 14,298,715.56 |
Wessex | 347,383,720.25 | 21,493,894.92 |
West Yorkshire | 382,578,532.72 | 20,116,489.08 |
Total | 7,691,396,925.17 | 460,145,956.79 |
Notes:
1This comprises the fees and allowances paid under Part IIIA: Professional Fees (Pharmacy Contractors) and Part VIA: Payment for Essential Services (Pharmacy Contractors) of the Drug Tariff. The medicine margin community pharmacies are allowed to earn as part of the payment for essential services, which is paid through reimbursement within the drugs’ bill, is not included.
2This comprises the fees paid to pharmacy contractors under Part VIC: Advanced Services (Pharmacy and Appliance Contractors)(England) of the Drug Tariff with the exception of the Community Pharmacy Seasonal Flu Vaccination Advanced Service and the NHS Urgent Medicine Supply Advanced Service pilot scheme, which are separately funded by NHS England.
A more detailed breakdown of fees and allowances paid for essential and advanced services provided by community pharmacies by NHS England Area from April 2013 to May 2017 is attached.
Asked by: Martyn Day (Scottish National Party - Linlithgow and East Falkirk)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what assessment he has made of the implications for his Department's policies of recommendations made by the Brain Tumour Charity in its report, Finding Myself: The Reality of Brain Tumour Treatment and Care, published in February 2016.
Answered by David Mowat
The recommendations made by The Brain Tumour Charity in its report and guidance align with the recommendations in the independent Cancer Taskforce’s 2015 report, Achieving World-Class Cancer Outcomes: A strategy for England 2015-20201, which represented the consensus views of the whole cancer community.
Improving early diagnosis of cancer is a priority for this Government. We have committed to delivering the independent Taskforce’s recommendations on early diagnosis, including the introduction of a 28 day waiting times standard. NHS England’s Accelerate, Co-ordinate, Evaluate programme is testing innovative ways of diagnosing cancer earlier. The second wave of the programme is piloting multi-disciplinary diagnostic centres for patients with vague or non-specific symptoms. The pilots are taking place in London, Greater Manchester, Leeds, Bristol, Oxfordshire and Airedale, Wharfedale and Craven (Yorkshire).
Additionally, patient experience was one of the six strategic priorities identified by the independent Cancer Taskforce, and ‘overall patient experience’ is one of the four key metrics included in the Clinical Commissioning Group Improvement and Assessment Framework published for the first time in 2016.
A new Department of Health Task and Finish Working Group on Brain Tumour Research is bringing together clinicians, charities, patients, and officials to discuss how, working together with research funding partners, we can address the need to increase the level and impact of research into brain tumours. The Working Group is chaired by Professor Chris Whitty, the Department's Chief Scientific Adviser. The Working Group met for the second time on 30 January, and plans to report to the Parliamentary Under Secretary of State for Public Health and Innovation by summer 2017.
The Department’s National Institute for Health Research (NIHR) supports brain tumour clinical trials via its Biomedical Research Centres, Clinical Research Facilities, and its Clinical Research Network (CRN). The CRN comprises 15 Local CRNs (LCRNs). In a new initiative from April 2015, each of these LCRNs has designated a senior clinician as the Subspecialty Lead for Brain Tumours. These local leaders are liaising with the National Cancer Research Institute’s Clinical Studies Groups to help plan the development and delivery of the national portfolio of brain tumour research, identifying new research opportunities and areas of clinical need. In the financial year 2015/16 the NIHR CRN supported recruitment of 1,061 patients to 37 brain cancer studies.
To support people after treatment ends, in December 2016, NHS England announced a fund of over £200 million available to Cancer Alliances over the next two years, specifically to support those areas of the Cancer Taskforce strategy that it estimated would need significant investment. This includes implementation of the Recovery Package so that patients have personalised care and support from the point they are diagnosed to improve their quality of life.
The report also included recommendations on palliative care. The Government’s ambition is for everyone approaching the end of life to receive high quality care that reflects their individual needs, choices and preferences. On 5 July 2016, we set out plans to improve end of life care in England. Our proposals are based on a commitment to high quality, personalised end of life care that we are making to all people at, or approaching the end of life.
Note:
Asked by: Martyn Day (Scottish National Party - Linlithgow and East Falkirk)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what assessment he has made of the implications for his Department's policies of recommendations made by the Brain Tumour Charity in its Patient Guide to Brain Tumour Treatment and Services, published in November 2016.
Answered by David Mowat
The recommendations made by The Brain Tumour Charity in its report and guidance align with the recommendations in the independent Cancer Taskforce’s 2015 report, Achieving World-Class Cancer Outcomes: A strategy for England 2015-20201, which represented the consensus views of the whole cancer community.
Improving early diagnosis of cancer is a priority for this Government. We have committed to delivering the independent Taskforce’s recommendations on early diagnosis, including the introduction of a 28 day waiting times standard. NHS England’s Accelerate, Co-ordinate, Evaluate programme is testing innovative ways of diagnosing cancer earlier. The second wave of the programme is piloting multi-disciplinary diagnostic centres for patients with vague or non-specific symptoms. The pilots are taking place in London, Greater Manchester, Leeds, Bristol, Oxfordshire and Airedale, Wharfedale and Craven (Yorkshire).
Additionally, patient experience was one of the six strategic priorities identified by the independent Cancer Taskforce, and ‘overall patient experience’ is one of the four key metrics included in the Clinical Commissioning Group Improvement and Assessment Framework published for the first time in 2016.
A new Department of Health Task and Finish Working Group on Brain Tumour Research is bringing together clinicians, charities, patients, and officials to discuss how, working together with research funding partners, we can address the need to increase the level and impact of research into brain tumours. The Working Group is chaired by Professor Chris Whitty, the Department's Chief Scientific Adviser. The Working Group met for the second time on 30 January, and plans to report to the Parliamentary Under Secretary of State for Public Health and Innovation by summer 2017.
The Department’s National Institute for Health Research (NIHR) supports brain tumour clinical trials via its Biomedical Research Centres, Clinical Research Facilities, and its Clinical Research Network (CRN). The CRN comprises 15 Local CRNs (LCRNs). In a new initiative from April 2015, each of these LCRNs has designated a senior clinician as the Subspecialty Lead for Brain Tumours. These local leaders are liaising with the National Cancer Research Institute’s Clinical Studies Groups to help plan the development and delivery of the national portfolio of brain tumour research, identifying new research opportunities and areas of clinical need. In the financial year 2015/16 the NIHR CRN supported recruitment of 1,061 patients to 37 brain cancer studies.
To support people after treatment ends, in December 2016, NHS England announced a fund of over £200 million available to Cancer Alliances over the next two years, specifically to support those areas of the Cancer Taskforce strategy that it estimated would need significant investment. This includes implementation of the Recovery Package so that patients have personalised care and support from the point they are diagnosed to improve their quality of life.
The report also included recommendations on palliative care. The Government’s ambition is for everyone approaching the end of life to receive high quality care that reflects their individual needs, choices and preferences. On 5 July 2016, we set out plans to improve end of life care in England. Our proposals are based on a commitment to high quality, personalised end of life care that we are making to all people at, or approaching the end of life.
Note:
Asked by: Rosena Allin-Khan (Labour - Tooting)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, for what reasons TB vaccinations are not available on the NHS to children in all London boroughs; and what the requirements are for boroughs to provide TB vaccinations by the NHS.
Answered by Baroness Blackwood of North Oxford
The implementation of the 2014 strategy to move to universal offer of Bacillus Calmette–Guérin (BCG) vaccination for all babies up to the age of one year in London has been interrupted by a global shortage of the BCG vaccine since April 2015. Public Health England has successfully secured an alternative unlicensed supply of BCG vaccine for the United Kingdom from a different manufacturer. As stocks remain restricted, NHS England has produced a protocol for delivery to those in the following priority groups:
- All infants (aged 0 to 12 months) with a parent or grandparent who was born in a country where the annual incidence of tuberculosis (TB) is 40/100,000 or greater.
- All infants (aged 0 to 12 months) living in areas of the UK where the annual incidence of TB is 40/100,000 or greater.
Asked by: Stephen Timms (Labour - East Ham)
Question to the Department for Education:
To ask the Secretary of State for Education, what steps the Government plans to take to protect state maintained schools in Greater London from the effect on their budgets of rising (a) staff and (b) other costs and real-terms funding reductions in 2016-17 and in 2017-18.
Answered by Nick Gibb
The Government recognises the importance of investing in education, and at the Spending Review confirmed a real terms protection for the core schools budget. Throughout this Parliament, the money available for our schools will increase as pupil numbers rise.
As with other public services, we recognise that schools are facing cost pressures from salary increases, the introduction of the National Living Wage, increases to employers’ National Insurance and Teachers’ Pension Scheme contributions and general inflation.
We are introducing a National Funding Formula to give greater certainty on funding and allow schools to plan ahead effectively. This is to ensure that resources are matched fairly and consistently across the country to school and pupil need.
We are also committed to providing support for schools to improve their levels of efficiency. In January we published a wide range of tools and support, available at:
https://www.gov.uk/government/collections/schools-financial-health-and-efficiency, and we will launch a school buying strategy to support schools to save over £1bn a year by 2019-20 on their non-staff spend.
Asked by: Lord Mawson (Crossbench - Life peer)
Question to the Department of Health and Social Care:
To ask Her Majesty’s Government what assessment they have made of the impact of their planned pharmacy cuts on patients and health services in the London Borough of Tower Hamlets.
Answered by Lord Prior of Brampton
Community pharmacy is a vital part of the National Health Service and can play an even greater role. In the Spending Review, the Government re-affirmed the need for the NHS to deliver £22 billion in efficiency savings by 2020-21 as set out in the NHS’s own plan, the Five Year Forward View. Community pharmacy is a core part of NHS primary care and has an important contribution to make as the NHS rises to these challenges. The Government believes efficiencies can be made without compromising the quality of services or public access to them. Our aim is to ensure that those community pharmacies upon which people depend continue to thrive and so we are consulting on the introduction of a Pharmacy Access Scheme, which will provide more NHS funds to certain pharmacies compared to others, considering factors such as location and the health needs of the local population.
The Government’s vision is for a more efficient, modern system that will free up pharmacists to spend more time delivering clinical and public health services to the benefit of patients and the public.
We are consulting the Pharmaceutical Services Negotiating Committee, other pharmacy bodies and patient and public representatives on our proposals. An impact assessment will be completed to inform final decisions and published in due course.
NHS England has a statutory duty to ensure the adequate provision of NHS pharmaceutical services across England and will ensure that duty continues to be met, including in respect of the London Borough of Tower Hamlets.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask Her Majesty’s Government which stakeholders were invited to the first meeting of the new Strategic Oversight Board.
Answered by Lord Prior of Brampton
The invitee list for the first Strategic Oversight Board meeting which took place on 18 November 2015 is below:
Name | Organisation |
Professor the Lord Ara Darzi of Denham (Chair) | Imperial College London |
Andrew Morris | Farr Institute |
Anna Beckett | Care Quality Commission |
Arvind Madan | Primary Care |
Bethan George | Tower Hamlets Clinical Commissioning Group |
Cynthia Clark | Patients 4 Data |
Dame Sally Davies | Department of Health |
Dawn Monaghan | Information Commissioner's Office |
Dr Aisling Burnand | Association of Medical Research Charities |
Dr Ben Goldacre | Bad Science |
Dr Grant Ingrams | British Medical Association |
Dr Janet Valentine | Clinical Practice Research Datalink |
Dr Mike Knapton | British Heart Foundation |
Eve Roodhouse | Health and Social Care Information Centre |
Gary Leeming | Greater Manchester Academic Health Science Network |
Gerard Crofton-Martin | Healthwatch England |
Jeremy Taylor | National Voices |
John Newton | Public Health England |
Katherine Rake | Healthwatch England |
Katie Farrington | Office of National Data Guardian |
Lisa Harrod-Rothwell | NHS England |
Louise Wood | Association of Medical Research Charities |
Neil Stutchbury | Monitor |
Nicola Perrin | Wellcome Trust |
Paul Bate | Care Quality Commission |
Prof John Appleby | The Kings Fund |
Prof Nigel Mathers | Royal College of General Practitioners |
Prof Simon Wessley | Royal College of Psychiatrists |
Prof Sue Bailey | Royal College of Psychiatrists |
Ronan O'Connor | NHS England |
Ros Roughton | NHS England |
Sarah Schofield | West Hampshire Clinical Commissioning Group |
Sir Bruce Keogh | NHS England |
Sir Cyril Chantler | UCL Partners |
Steven Black | Monitor |
Asked by: Sadiq Khan (Labour - Tooting)
Question to the Department for Levelling Up, Housing & Communities:
To ask the Secretary of State for Communities and Local Government, how many public health funerals were there in each London borough in each year since 2010.
Answered by Marcus Jones - Treasurer of HM Household (Deputy Chief Whip, House of Commons)
The Department for Communities and Local Government does not collect the information requested.